drugset
drugset / Trial / NCT05440344

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

NCT05440344 ↗

Phase 1 Completed 27 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female participants with normal liver function. The side effects and tolerability of Imlunestrant will also be evaluated. The study may last up to 46 days for each participant.

Timeline

Start
2022-07-05
Primary completion
2024-02-28
Completion
2024-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Imlunestrant Small molecule 200 mg Oral
Subject Imlunestrant Small molecule 400 mg Oral

Indications

liver disorder